WASHINGTON — The FDA on Friday spelled out exactly what kind of studies biosimilar drug makers must conduct in order to be considered “interchangeable” with a biologic drug the way a generic functions for a normal medicine.

It’s the agency’s final word on a controversial and long-running fight over how it will define those rules for the pricey category of biologic drugs, the complex drugs made from living organisms used to treat conditions like cancer, and their copycat biosimilars.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • what is largely not understood, even by prescribers, is that each manufactured lot of any biologic is not exactly the same as another. There is unavoidable variability due to the process involved with manufacturing a biologic. Just the requirement for a biosimilar to do studies signals that they may somehow be significantly different from the originator biologic, which is both not true and also plays right into the narrative originator biologics have been telling for years in order to protect their lucrative business. It has worked (so far) and FDA is complicit. Meanwhile patients and taxpayers are having their pockets picked.

    • just to clarify the intent of the first sentence above, each lot of an originator biologic will inevitably be different from the prior one. If biosimilars need to do interchangability studies, then you can also argue that originators need to do the same with different lots. It’s silly.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy